SS18 and synovial sarcoma: Recent evidence suggests that targeting of histone deacetylase (HDAC) family members, and of HDAC2 in particular, facilitates SS18-SSX degradation and inhibits its oncogenic activity in synovial sarcoma cells (Patel et al., 2019).